The recent introduction of the second-generation long-acting analogue insulins degludec and insulin glargine U300 have increased the choice of basal insulin therapy for patients with type 2 diabetes. The pharmacokinetic and pharmacodynamic properties of these insulins result in a flatter profile that lasts over 24 h and provides an increased window of administration of 6 h once daily. Large-scale multicentre randomised clinical trial programmes (BEGIN for degludec U100 and U200 and EDITION for glargine U300) evaluating these insulin therapies against glargine U100 have demonstrated that they are either non-inferior or superior for glycaemic efficacy and safety, but less likely to result in severe or nocturnal hypoglycaemia than glargine U100. The disposable pen devices for these insulins have been designed with patient satisfaction and convenience in mind. No concerns have arisen with adverse events with insulin analogues or cardiovascular safety from the ORIGIN and DEVOTE trials. As they demonstrate equivalent glycaemic efficacy to other basal insulins, they should be considered more in selected patient groups including those with recurrent or increased risk of hypoglycaemia, especially severe or nocturnal episodes, in the elderly or those living alone, and in patients with multiple co-morbidities such as cardiovascular or renal disease.
Introduction

Background and Rationale for Development of Concentrated Insulin
Since the discovery of insulin by Banting and Best in 1921 [1] , there has been a continuous process in improved development of insulin therapy [2] . Near physiological insulin replacement improves glycaemic excursions and reduces microvascular and macrovascular complications in people with diabetes [3] . Basal insulin therapy is currently recommended as an option following metformin when glycaemic targets are not reached in patients with type 2 diabetes (T2DM) and in combination with dual oral or other injectable glucose-lowering therapy or as part of a basal bolus regimen [4] . For insulin initiation, basal insulin is recommended in preference to pre-mixed or prandial insulins as glycaemic efficacy is not limited by excessive hypoglycaemia or weight gain as demonstrated in the 4T study [5] . The ideal longacting basal insulin has a relatively flat profile with minimal intra-individual and inter-individual variability, and without resulting in excessive hypoglycaemia and weight gain. Long-acting basal insulins have been available for more than 50 years in the form of Neutral Protamine Hagedorn (NPH) insulin, with the more recent introduction of analogue insulins such as glargine U100 (100 units/ml) and detemir. A retrospective observational study of 25,489 patients with T2DM initiated on basal insulin therapy comparing initiation of insulin glargine U100 or detemir with NPH insulin found no difference in risk of hypoglycaemia-related emergency department visits or glycaemic efficacy [6] .
In the last 5 years, second-generation ultra-long-acting highly concentrated basal insulins have been introduced, namely degludec U100 and U200 (Tresiba ® , NovoNordisk) and insulin glargine U300 (Toujeo ® , Sanofi-Aventis), which is three times more concentrated than glargine U100. These new generation basal insulins have no action peak and both intra-individual and inter-individual variability are reduced compared with older long-acting insulins (Fig. 1) . Another ultra-long-acting basal insulin, PegLispro, demonstrated clinically relevant improvements in glycaemic efficacy with significant reduction in nocturnal hypoglycaemia compared to NPH insulin in phase III trials [7] , but this was discontinued in 2017 due to adverse effects including insulin site reactions and abnormal liver transaminase and triglyceride levels [8] .
Effective insulin therapy improves glycaemic control and reduces the development and progression of complications. However, hypoglycaemia and weight gain are significant adverse effects of insulin therapy. With time, the pharmacokinetic profiles of basal insulins have improved leading to fewer peaks and troughs and variability, which reduces the risk of hypoglycaemia and increases patient safety. Nevertheless, the relatively higher costs of the highly concentrated insulins need to be balanced against their benefits compared with more established basal insulins such as glargine, detemir and NPH insulin especially, as 80% of people with T2DM live in low-to middle-income countries [9] . Notably, insulin degludec can be up to 50-70% more expensive than other basal insulins and up to approximately 15% higher doses of insulin glargine 300 are required compared with insulin glargine U100, increasing the overall cost [10] .
This review describes the long-acting concentrated insulins degludec U100 and U200 and glargine U300 and discusses their place in the management of patients with T2DM.
Insulin Degludec (Tresiba®)
Insulin degludec has been approved for use in Europe since 2013 and the USA since 2015 and is also now widely available in Asia and Latin America. The ultra-long duration of action of degludec U100 and U200 results from the stabilising action of low concentrations of phenol and increased albumin binding resulting in the formation of hexamers following subcutaneous injection, which slowly break down into dimers and monomers prior to absorption into the bloodstream [11] . The soluble multihexamers result from changes in the amino acid structure of insulin, specifically deletion of the B30 threonine molecule and formation of a covalent linkage with glutamic acid between B29 lysine and a C16 fatty acid [2] . Reassuringly, it has been shown experimentally that degludec has a low mitogenic-to-metabolic potency ratio [12] . The plasma half-life of degludec is 25 h, which is nearly double that of insulin glargine U100 [13] .
Glycaemic Efficacy
There have been several open-label, randomised controlled phase III trials investigating insulin degludec U100 and U200 compared with insulin glargine U100 in patients with T2DM in both insulin-naïve populations and those already on insulin therapy (Table 1) [14] [15] [16] [17] [18] . In summary, the trials Reduced risk of hypoglycaemia especially nocturnal episodes compared with insulin glargine U100
Non-inferior glycaemic efficacy compared with glargine U100
No safety concerns regarding cardiovascular disease or cancer Glargine U300 Degludec U100/U200 demonstrate non-inferiority for glycaemic efficacy parameters between degludec U100 or U200 and glargine U100. The head-to-head BEGIN Basal-Bolus Type 2 study of degludec U100 with glargine U100 in T2DM demonstrated equal efficacy with superiority of degludec in reduction in nocturnal hypoglycaemia due in part to reduced intra-individual variability [14] . In this 52-week phase III open-label, treat-to-target, non-inferiority trial of 1006 participants with T2DM randomly allocated to either degludec or glargine U100, there was a glycated haemoglobin (HbA1c) reduction at study end of 1.1% in the degludec arm and 1.2% in the glargine arm (estimated treatment difference [ETR] 0.08%; 95% CI − 0.05 to 0.21).
In the 52-week BEGIN Once Long trial of insulin-naïve participants on oral glucose-lowering therapy with the exception of thiazolinediones randomised to either insulin degludec U100 or glargine U100, there was no difference in glycaemic efficacy between the two insulins in terms of HbA1c reduction or fasting plasma glucose (FPG) levels, but there was a significant reduction in nocturnal hypoglycaemia rates with degludec [15] . In the BEGIN Low Volume randomised controlled trial there were no significant differences in glycaemic efficacy (HbA1c and FPG) or hypoglycaemia rates between insulin degludec U200 and glargine U100 [16] . In the BEGIN Once Asia trial, similar results were seen to those with the BEGIN Once Long trial for non-inferior glycaemic efficacy between the two basal insulins, although insulin degludec U200 was superior in reducing nocturnal hypoglycaemia [17] .
The SWITCH 2 crossover study was a 16-week randomised clinical trial consisting of 721 patients with T2DM and at least one hypoglycaemia risk factor who were previously treated with basal insulin with or without glucose-lowering therapy and where glycaemic efficacy was a secondary endpoint [18] . The hypoglycaemia risk factors included at least one severe hypoglycaemic episode in the last 12 months, hypoglycaemia unawareness, moderate chronic renal impairment, insulin therapy for more than 5 years or symptoms and/or blood glucose level of ≤ 3.9 mmol/L (70 mg/dl) in the last 12 weeks. At study end, insulin degludec was non-inferior to glargine U100 in HbA1c reduction for treatment period 1 (7.06% vs. 6.98%, respectively, 95% CI − 0.04% to 0.23%, p < 0.001 for noninferiority) and treatment period 2 (7.08% vs. 7.11%, respectively, − 0.07% to 0.18%, p < 0.001).
Hypoglycaemia
Hypoglycaemia affects the well-being and quality of life of people with diabetes and is also a highly feared side effect of treatment, which limits the ability to achieve optimal glycaemic control [19] . The consequences of hypoglycaemia such as falls, paramedic call-outs and hospital admissions can also overburden health service resources. Managing severe hypoglycaemia has been shown to be more expensive for insulin-treated T2DM patients than for type 1 diabetes (T1DM) patients in three European countries [20] . Nocturnal hypoglycaemia in particular can be particularly dangerous, especially in people who live on their own or have reduced counter-regulatory responses such as the elderly [21] . A large 'real-world' observational study of 55,608 patients with T2DM in the USA showed that hypoglycaemia was experienced by up to 4.5% of people within 6 months of initiation with basal insulin, resulting in treatment discontinuation and increased healthcare utilisation and costs such as hospitalisation [22] .
A pre-specified meta-analysis of the phase III programme of degludec studies has confirmed that the rates of overall and nocturnal-confirmed hypoglycaemic events were 17% and 32% less frequent, respectively, with insulin degludec compared with insulin glargine U100 at similar HbA1c concentrations [23] . However, the authors acknowledged that the open-label design and exclusion of participants with recurrent severe hypoglycaemia were limitations of the meta-analysis.
In the BEGIN Basal-Bolus Type 2 study, rates of severe hypoglycaemia were similar for the two basal insulins (0.06 vs. 0.05 episodes per patient-year exposure degludec vs. glargine), and the main difference was in the rate of nocturnal-confirmed hypoglycaemia for degludec versus glargine (1.4 vs. 1.8 episodes per patient-year exposure; estimated rate ratio 0.75, 0.58-0.99, p < 0.05) and overall hypoglycaemia (11.1 vs. 13.6 episodes per patient-year exposure, 0.82, 0.69-0.99, p < 0.05) [14] .
Overall symptomatic hypoglycaemia was also less frequent with insulin degludec than with glargine U100 in the SWITCH 2 double-blind randomised controlled 64-week crossover trial comprising 721 participants with T2DM [18] . Notably, to be recruited, participants had to have at least one of five hypoglycaemia risk factors including at least one severe hypoglycaemic episode in the last 12 months, moderate chronic renal failure (eGFR 30-59 ml/min/1.73 m 2 ), hypoglycaemic unawareness, insulin treatment duration > 5 years or episode of hypoglycaemia (symptoms and/ or blood glucose ≤ 3.9 mmol/L in the last 3 months). The primary endpoint of this trial was the rate of overall symptomatic hypoglycaemia during the 16-week maintenance period, which was either a severe externally adjudicated episode defined as requiring third-party assistance or a confirmed blood glucose of < 3.1 mmol/L. In patients randomised to insulin degludec, the rate of overall symptomatic hypoglycaemia was 185.6 episodes versus 265.4 episodes in those on glargine U100 per 100 patient-years of exposure [estimated rate ratio (ERR) = 0.70, 95% CI 0.61-0.80, p < 0.001]. For nocturnal hypoglycaemia, episodes were 55.2 for degludec versus 93.6 for insulin glargine U100 per 100 patient-years of exposure (ERR 0.58, 0.46-0.74, p < 0.001). However, there was no difference between the two insulins for severe hypoglycaemia during the maintenance period (ERR 0.54, 0.21-1.42, p = 0.35).
A systematic review has confirmed that there is a 10% lower insulin dose requirement with degludec compared with glargine U100 and detemir, which may explain the reduction in hypoglycaemia [24] . Post-hoc analysis of SWITCH 2 demonstrated that lower doses of insulin degludec were required after 32 weeks of treatment compared with insulin glargine U100 (p < 0.001) [18] .
The US Food and Drugs Administration (FDA) has been cautious about the evidence regarding reduction in nocturnal hypoglycaemia with insulin degludec compared with insulin glargine U100 on the basis of lack of consistency across trials in terms of hypoglycaemia definition and study populations as well as differences in pharmacokinetics and pharmacodynamics of the insulins. Moreover, a 2-h extension of the nocturnal period minimised the difference in hypoglycaemia between these insulins [10] .
A systematic review and network meta-analysis of 39 trials comprising 26,195 patients with T2DM found low and very low quality evidence that reduced risk of nocturnal hypoglycaemia was associated with degludec U100 and U200 and glargine 300 [25] .
Weight
Weight gain is a significant unwanted side effect of insulin therapy. In the BEGIN Basal Bolus Type 2 trial, mean weight gain was similar for both insulins at the end of the study, with patients on degludec gaining 3.6 kg (SD 4.9 kg) and patients on glargine U100 gaining 4.0 kg (SD 4.6 kg) [14] .
Similarly, in the SWITCH 2 crossover study, there was no significant difference in weight between insulin degludec and insulin glargine U100 in either treatment period, which was 1.5 kg and 0.5 kg for degludec and 1.8 kg and 0.9 kg for glargine at the ends of treatment periods 1 and 2, respectively (p = 0.32 and p = 0.29 respectively) [18] .
Cardiovascular Safety
Since 2008, all new glucose-lowering therapies need to be tested in robust cardiovascular outcome safety trials as required by the FDA. More recently the results of the cardiovascular outcome study for the degludec A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) has confirmed that degludec is non-inferior to insulin glargine U100 for cardiovascular safety based on the primary major adverse cardiovascular composite outcome of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (hazard ratio 0.91, 95% CI 0.78-1.06) [26] . In this study of 7637 patients with T2DM, participants were either over 50 years of age with pre-existing cardiovascular disease (CVD) or over 60 years of age with CVD risk factors, with a mean age of 65.0 years and a mean duration of T2DM of 16.4 years. A further notable finding was that use of degludec was associated with significantly lower rates of severe and nocturnal hypoglycaemia compared with glargine U100 (3.70 vs. 6.25 events per 100 patient-years).
Glargine U300 (Toujeo®)
Glargine U300 was approved globally for use in T2DM in 2015. As a consequence of low intra-individual variability ranging between 17% and 35%, glargine U300 has a relatively peakless profile and greater diurnal reproducibility [27] .
Glargine U300 (300 units/ml) is three time more concentrated than glargine U100 (100 units/ml) and this impacts on the pharmacokinetic and pharmacodynamic properties of the newer formulation. Key differences are in the size of the subcutaneous depot, which for glargine U300 is twothirds in volume and half the surface area of glargine U100. These effects lead to slower degradation of insulin molecules consequently retarding insulin absorption. The half-life of glargine U100 is 12 h whereas for glargine U300 it is 19 h. There is a 6-h window for injecting glargine U300 while retaining glycaemic efficacy and this enables greater flexibility in dose timing for patients with T2DM.
Glycaemic Efficacy
Glargine U300 has been extensively evaluated in a programme of multicentre randomized clinical trials (EDI-TION) including people with T2DM in North and South America, Europe, South Africa and Japan using glargine U100 as a comparator (Table 2 ) [28] [29] [30] [31] . In the EDITION 1 trial [28] , eligible participants were on ≥ 42 units/day of either NPH insulin or glargine U100 plus mealtime insulin (lispro, aspart, gliulisine); in EDITION 2 [29] , participants were on basal insulin (≥ 42 units/day) and oral glucoselowering therapy; and in EDITION 3 [30] participants were insulin-naïve. Finally, the Japanese population in the EDITION JP 2 trial were on basal insulin and oral glucoselowering therapy for at least 6 months with no pre-specified basal insulin dose [31] .
A patient-level meta-analysis of 2496 participants in the EDITION 1, 2 and 3 studies identified that glargine U300 is non-inferior to glargine U100 for mean change in HbA1c at 6 months [each − 1.02 (standard error 0.03) %; least squares mean difference 0.00 (95% CI − 0.08 to 0.07)] [32] .
A similar proportion reached the HbA1c target of < 7.0% at study end (36.2% for glargine U300 and 35.5% for glargine U100). Fasting plasma glucose decreased similarly with both insulin formulations (least squares (LS) mean difference 0.21, 95% CI 0.03-0.40 mmol/L).
In summary, there was no statistically significant difference between insulin glargine U100 and U300 in terms of glycaemic efficacy identified in the phase III trial programme.
Hypoglycaemia
In the pooled analysis of the EDITION 1, 2 and 3 trials, lower rates of hypoglycaemia were seen with glargine U300 compared with glargine U100 throughout the 24-h period [32] . For insulin glargine U300, there were 15.22 events per participant-year for confirmed (≤ 3.9 mmol/L) or severe hypoglycaemia and for glargine U100 17.73 events per participant-year (rate ratio 0.86, 95% CI 77-0.97, p = 0.0116), reflecting a 14% difference favouring glargine U300. Nocturnal hypoglycaemic episodes between 00.00 and 05.59 h were fewer with glargine U300, but most events were reported between 0.600 and 14.00 h with 8.14 events per participantyear for glargine U300 and 10.13 events per participant-year for glargine U100, especially between 06.00 and 10.00 h. Episodes of severe hypoglycaemia were relatively few with 0.11 events per participant-year in both groups (rate ratio 0.98, 95% CI 0.51-1.86) equating to 28 (2.3%) in the glargine U300 group and 33 (2.6%) in the glargine U100 group (relative risk 0.85, 95% CI 0.52-1.39). There was no difference in hypoglycaemia rates between older participants aged > 65 years and those in younger age groups.
In the pooled analysis of the EDITION 1, 2 and 3 trials, there was an increase in basal insulin dose of 0.85 U/kg/ day with glargine U300 and 0.76 U/kg/day with glargine U100, which reflects a 12% increased dose with glargine U300 [32] . This is in contrast to the insulin dose reduction seen in trials with degludec.
Weight
In the pooled analysis of the EDITION 1, 2 and 3 trials, less weight gain was seen with glargine U300 than with glargine U100 (LS mean difference − 0.28, 95% CI − 0.55 to − 0.01, p = 0.039) [32] .
Cardiovascular Safety
The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, which predates the FDA mandate for cardiovascular safety outcome trials, provides reassurance for the cardiovascular safety of glargine U300 based on data for glargine U100 [33] . The 6-year ORIGIN trial was also able to demonstrate that cancer risk was very low for glargine U100 and by extension glargine U300. Furthermore, the ORIGIN-GRACE substudy confirmed that glargine U100 was associated with a reduced progression in carotid-intima thickening, which is a surrogate for cardiovascular disease [34] .
Head-to-Head Studies
Randomised Trials
The BRIGHT trial is the first reported head-to-head noninferiority study between insulin glargine U300 and insulin degludec U100 in insulin-naïve T2DM patients [35] In this open-label 24-week parallel-group study, 929 participants with T2DM on any glucose-lowering agents including SGLT-2 inhibitors and GLP-1 receptor agonists were randomised to evening dosing of either long-acting insulin with up-titration to maintain a FPG of 4.4-5.5 mmol/L (80-100 mg/dl).
At study end there was no difference in the glycaemic improvement from baseline between insulin glargine U300 and degludec U100 [HbA1c 7.0% (53 mmol/mol), p < 0.0001]. In the active titration period, there was a lower incidence and rate of hypoglycaemia over the 24-h period with glargine U300, but there were no differences between the two insulins in the maintenance period (weeks 13-24), although hypoglycaemia was more likely in patients on sulphonylureas or meglitinides at screening. Apart from one episode of severe hypoglycaemia with glargine U300 there were no other significant adverse effects or safety issues for either insulin. At study end, absolute mean weight gain was 2.0 ± 3.8 kg with glargine U300 and 2.3 ± 3.6 kg with degludec U100.
In a small Japanese trial of 24 participants with T2DM randomised to either glargine U300 or degludec U100 where the primary endpoints were hypoglycaemia and mean percentage of time spent in target glucose range as assessed by flash glucose monitoring over 14 days, there was no significant difference between the insulins for glycaemic efficacy, although insulin glargine U300 was associated with significantly lower rates of nocturnal hypoglycaemia (p = 0.007) [36] . The same researchers found similar results in another 30 patients with T2DM when these insulins were compared for glycaemic efficacy and hypoglycaemia using continuous glucose monitoring over 5 days [37] .
These trials provide evidence that insulin glargine U300 and insulin degludec are non-inferior to each other in terms of glycaemic efficacy, although hypoglycaemia risk may vary and the choice between them will depend on cost, availability, and patient and clinician preference. 
Real-world Studies
In the DELIVER-D retrospective observational study of data on 1592 patients with T2DM from 39 integrated US healthcare databases, glycaemic efficacy and safety data were collected for patients switching from glargine U100 to glargine U300 or degludec [38] . As seen in the BRIGHT randomised controlled trial, no significant difference was observed in glycaemic effectiveness or hypoglycaemia incidence or event rates between the two insulin therapies. In another real-world study of 42,001 US patients switching from firstgeneration basal insulins to either insulin glargine U300 or degludec, predictive modelling demonstrated no difference in rates of severe hypoglycaemia between the two newer insulins, providing further reassurance that either one is an appropriate choice in terms of hypoglycaemia data [39] .
Clinical and Practical Considerations
Delivery Device
Ease and convenience of insulin administration is greatly facilitated by the use of a robust and well-designed delivery device. Few patients use insulin syringes in the modern era, and insulin injection pens that are either disposable or reusable with cartridges are the preferred delivery device. Patient choice with regard to delivery device is important when considering basal insulin therapy provided that the appropriate insulin is selected based on clinical and patient factors. The patient should be given the opportunity to test out the device under healthcare professional supervision to ensure that it is comfortable and used correctly. Glargine U300 (Toujeo ® ) is available in two pen options: SoloStar ® , which delivers 450 units of insulin per pen in 1-unit increments, and Max SoloStar ® , delivering 900 units per pen in 2-unit increments [40] . If a patient needs at least 20 units of insulin per day, Max SoloStar ® is the recommended device. In a small multicentre German study of 40 insulin-and pen-naïve patients with T2DM administering glargine U300 with the SoloStar ® pen for 4 weeks, 95% of participants reported the pen as excellent/good, and generally easy to learn and easy to use, and there were no technical problems or adverse events associated with the device [41] .
Degludec (Tresiba ® ) is also available in two pen options: FlexTouch ® U100, which contains 300 units per pen in 1-unit increments, and FlexTouch ® U200, which contains 600 units but delivers the same dose in half the volume of the U100 pen and allows 2-unit dose adjustments [42] . The FlexTouch ® pen has a lower injection force, no push-button extension and an end-of-dose click, and it was preferred to other insulin pen devices in usability studies in terms of ease of learning and use for patients and teaching to use by healthcare professionals [43] .
In a randomised multicentre crossover study including 42 patients with T2DM and 22 patients with T1DM, 32 nurses and 32 physicians, FlexTouch 100 ® and FlexTouch 200 ® were preferred over SoloStar ® for administering injections into a foam cushion at different increasing insulin doses [44] .
Patient Adherence to Treatment
Patient factors such as injection difficulties, lifestyle burden, regimen complexity and inflexibility, and practical barriers must all be considered and addressed when choosing appropriate insulin regimens if patient adherence is to be optimised [45] . Fear of hypoglycaemia is a significant barrier to initiating and maintaining insulin therapy and has been described as 'psychological insulin resistance' [46] . Patient education has been shown to improve healthcare behaviours such as treatment adherence, and people with T2DM should be strongly encouraged to attend diabetes structured education programmes [47] . Healthcare providers also need appropriate training on newer insulin therapies, dose adjustment, injection devices and needles to adequately support patients [48] . The use of simple insulin intensification algorithms can support more rapid escalation of insulin doses to achieve glycaemic targets safely and effectively [49] . Reducing clinical inertia around initiation and intensification of basal insulin is a key component of optimising insulin therapy [50] .
In the EDITION 1 trial where patients with T2DM who were already on ≥ 42 units daily of either NPH insulin or glargine U100 with any prandial insulin at baseline were randomised to either glargine U300 or U100 over 6 months, treatment satisfaction scores did not differ between treatment groups and increased for both insulins by study end [28] . In EDITION 2, where participants were on basal insulin and oral hypoglycaemic agents before being randomised to either glargine U300 or U100, there were no differences in treatment satisfaction or perceived frequency of hypoglycaemia between the two insulins [29] . Participant-reported outcomes reported in the EDITION 3 trial of insulin-naïve patients with T2DM randomised to either glargine U300 or glargine U100 did not find a difference in health-related quality of life between these insulins, and fear of hypoglycaemia decreased with both strengths of insulin over the 6-month study period [30] . Use of glargine U300 has been shown to be associated with improved quality of life compared with glargine U100 [28, 30, 51] .
A small qualitative study of 20 adults with T2DM from the USA and Switzerland who underwent 90-min interviews after being on insulin degludec for at least 3 months reported "feeling better", in particular due to á greater sense of wellbeing, enhanced feelings of adaptability and freedom, reduced sense of diabetes burden and increased sense of security, especially with regard to hypoglycaemia [52] .
Duration of Action
The duration of action is a critical factor in the effectiveness of basal insulin in maintaining glycaemic targets in the fasting state and overnight [53] . NPH insulin has a duration of action of around 12-18 h, whereas insulin detemir and glargine are present within the blood stream for up to 24 h. The ultra-long-acting insulins glargine U300 and degludec U100 and U200 have significantly longer durations of action at 32 and 42 h, respectively [54, 55] . NPH insulin, glargine U100 and detemir are usually administered once or twice daily, whereas glargine U300 and degludec U100 and U200 are administered once a day. There is a greater administration window for the ultra-long-acting insulins, which can be taken within a 4-to 6-h period. These characteristics increase flexibility and convenience insulin injections for patients.
Timing of Administration and Switching from First-generation Basal Insulins
The pharmacokinetic profile of concentrated basal insulins allows for a longer window for timing of administration. This can improve patient adherence as it leads to increased flexibility of insulin injections depending on occupational and social circumstances. For glargine U300 the window for insulin administration is up to 6 h [28, 30] . The phase III clinical trials for glargine U300 showed that hypoglycaemia was most likely to occur between 6.00 am and 10.00 am if administered at bedtime [32] . A 26-week study, in which patients with T2DM who were either insulin-naïve or on insulin glargine U100 were randomised to different pre-specified dosing schedules of insulin degludec allowing for 8-to 40-h intervals between injections, demonstrated that there was no compromise in glycaemic control or safety with such an exaggerated dosing window for patients on insulin degludec [56] .
Basal insulin is associated with greater insulin treatment satisfaction than prandial insulin [57] . Glargine U300 is administered once daily and is available in a pre-filled pen with which up to 80 units can be administered in 1-unit increments. In insulin-naïve patients the recommended starting dose of glargine U300 is 0.2 units per kg body weight once daily, and in those already on insulin therapy, the same unit dose as the previous once-daily intermediate or longacting insulin can be administered (Fig. 2) [58] . However, if the patient is on a twice-daily NPH insulin, it is recommended that 80% of the total daily NPH dose is administered for glargine U300 to minimise the risk of hypoglycaemia. Higher doses of glargine U300 are usually required, around 12% higher by 6 months [32] and 14% higher by 12 months [59] , compared with glargine U100, according to clinical trial data.
Insulin degludec U100 and U200 are both administered as once-daily injections using pre-filled pens that dose in 1-unit increments, specifically up to 80 units with U100 and up to 160 units with U200 (Fig. 2) . In insulin-naïve patients, the starting dose of 10 units once daily is recommended, whereas those already on insulin therapy can administer For hypoglycaemia determine and address cause and reduce dose by 4 units or 10-20%.
Fig. 2
Flow chart for initiating second-generation basal insulin therapy [58, 60] the same unit dose as the total daily long-or intermediateacting insulin unit dose [60] . Notably, no reduction in dose is required if switching between degludec U100 and U200 [53] .
Patient Groups Most Likely to Benefit
The choice of basal insulin is determined by a number of insulin factors including glycaemic efficacy, hypoglycaemia risk, weight gain and cost, and patient factors such as ease of use, convenience in insulin timings and patient satisfaction. A recent systematic review and network meta-analysis found high-to-moderate evidence that detemir leads to less weight gain compared with all other basal insulins including degludec and glargine U300, and low and very low quality evidence that degludec and glargine U300 were associated with a lower incidence of nocturnal hypoglycaemia than detemir and glargine U100 [25] . Significantly this comprehensive meta-analysis of 39 trials including 26,195 participants with T2DM did not find significant evidence that any basal insulins were superior in terms of glycaemic effects or severe hypoglycaemic episodes. It must be noted that insulin degludec had higher rates of severe hypoglycaemia in the SWITCH 2 crossover randomised controlled trial than insulin glargine U300 in the EDITION 2 randomised controlled trial [18, 29] . It would be appropriate to consider the second-generation basal insulins when recurrent nocturnal hypoglycaemia is affecting the safety and quality of life of a patient with T2DM. Additionally, patients who rely on insulin administration from district or community nursing teams may be appropriate for these insulins because of the prolonged administration windows of 4-6 h without affecting glycaemic efficacy. Other patient groups likely to benefit from these second-generation basal insulins are those with multiple co-morbidities such as cardiovascular disease or chronic renal disease [61] .
Potential Dispensing and Administration Errors
Familiarity with different insulin formulations and strengths is essential if dispensing errors are to be avoided resulting in harm to patients with T2DM. To reduce confusion, various strengths of higher concentration insulins are colourcoded differently. Insulin prescribing errors are particularly prevalent during hospital admissions [62] . Insulin glargine U300 (Toujeo ® ) can be easily mistaken for glargine U100 (Lantus ® ) and incorrect doses given. Similarly, as degludec is available in two strengths, U100 and U200, clear documentation is required to ensure that the correct formulation is prescribed and administered. Appropriate education of patients and carers regarding the type, administration and characteristics of the insulin prescribed will help to minimise insulin-related errors.
Outlook for Future Treatment Options
Cost is a major factor with regard to future widespread prescription of these highly concentrated basal insulins. Compared with insulin glargine or detemir, degludec is up to 70% more expensive in some European countries such as the UK [10] . Although glargine U300 has a comparable cost to glargine U100, nearly 15% higher doses are required to achieve equivalent glycaemic efficacy [59] . However, it has been estimated that quality of life is improved with insulin degludec in T2DM patients (0.0065 quality-adjusted lifeyears [QALYs] gain) when compared with insulin glargine U100 with an incremental cost-effectiveness ratio of £17,939 and an increased annual cost of £117 [63] . An economic evaluation of the DEVOTE trial found that in patients with a high risk of cardiovascular events, degludec was cost-neutral when compared with glargine U100 over 2 years with a mean improvement of 0.0064 QALYs mainly due to reduced rates of severe hypoglycaemia with degludec [64] .
However, as clinical trials have shown that the main benefit is in reducing hypoglycaemia rather than increased glycaemic efficacy when compared with other basal insulins, there is no indication to choose these insulins as the first line in the majority of patients with T2DM.
There is increasing interest in the combination of ultralong-acting insulins with GLP-1 receptor agonists as these formulations reduce hypoglycaemia risk and weight gain and also limit the insulin dose required for the same glycaemic effect. Fixed formulations of these agents such as IDegLira or degludec with liraglutide have been tested in large clinical trials and are now available for use in T2DM [65] .
Conclusion
Ultimately, successful initiation and intensification of insulin is dependent on appropriate patient selection and education with timely dose adjustment according to dietary patterns, hypoglycaemia, weight and physical activity to reach safe and acceptable glycaemic targets. The second-generation ultra-long-acting basal insulins degludec U100 and U200 and glargine U300, which have a greater than 24-h duration of action, reduced peak action profile and intra-individual and inter-individual variability, represent an incremental benefit in the management of patients with T2DM. The main benefits to patients are their equivalent glycaemic efficacy and safety profile with first-generation basal insulins coupled with significant improvements in the flexibility of dose timing and reduced risk of hypoglycaemia especially nocturnal episodes. However, the evidence of these benefits needs further support from high-quality randomised controlled trials and observational studies as some controversies remain around the extent of reduction in hypoglycaemia and the fact that degludec in particular represents a relatively expensive option for basal insulin therapy compared with other insulins on the market. The margin of benefit with these second-generation insulins may be modest for most patients and therefore careful patient selection and appropriate education and support are important to achieve maximal efficacy and cost-effectiveness.
